Company / Financials
Clearside Biomedical, Inc. Financials
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$1.7M
FY2024 · -79.8% YoY
Net Income
-$34.4M
FY2024 · -5.7% YoY
Profit Margin
-2064.4%
FY2024 · net income / revenue
ROE
-
FY2024 · return on equity
Total Assets
$25.1M
FY2024
Total Debt
-
FY2024
Equity
-$38.9M
FY2024
ROA
-136.7%
FY2024 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -15.27 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$1.7M-79.8% YoYNet Income HistoryProfit after all expenses and taxes-$34.4M-5.7% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$149.0K-58.0% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$28.9M-16.3% YoYSG&A Expense HistorySelling, general, and administrative expenses$11.8M-0.5% YoYR&D Expense HistoryResearch and development spending$18.6M-10.8% YoYEPS (Basic) HistoryBasic earnings per share-$0.55-5600.0% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$0.55-5600.0% YoYShares Outstanding HistoryWeighted average diluted shares outstanding62.9M+3.6% YoYTotal Assets HistoryTotal value of all assets owned$25.1M-26.1% YoY